Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.
An expert analyst still thinks BridgeBio is worth buying, but cut the expected price in half. This usually means the company's future looks less exciting than before, even though the analyst still believes in it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.